Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of “Buy” by Analysts

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given a consensus recommendation of “Buy” by the ten ratings firms that are covering the stock, Marketbeat reports. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $51.40.

A number of equities analysts have recently commented on DYN shares. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, September 16th. Piper Sandler lifted their target price on Dyne Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Oppenheimer reiterated an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. raised their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research report on Tuesday, July 9th. Finally, Morgan Stanley upped their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th.

Insider Buying and Selling at Dyne Therapeutics

In related news, SVP Richard William Scalzo sold 1,390 shares of the company’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total transaction of $48,024.50. Following the completion of the sale, the senior vice president now directly owns 98,568 shares in the company, valued at approximately $3,405,524.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Dyne Therapeutics news, CEO John Cox acquired 32,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were purchased at an average cost of $33.04 per share, for a total transaction of $1,057,280.00. Following the transaction, the chief executive officer now owns 8,000 shares in the company, valued at $264,320. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Richard William Scalzo sold 1,390 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now directly owns 98,568 shares in the company, valued at $3,405,524.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,868 shares of company stock worth $796,760. 20.77% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. bought a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $140,666,000. Janus Henderson Group PLC boosted its holdings in shares of Dyne Therapeutics by 23,512.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,675,240 shares of the company’s stock valued at $75,915,000 after buying an additional 2,663,910 shares in the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Dyne Therapeutics in the 4th quarter worth about $15,758,000. Price T Rowe Associates Inc. MD increased its stake in shares of Dyne Therapeutics by 8,284.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,132,092 shares of the company’s stock worth $32,141,000 after acquiring an additional 1,118,590 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Dyne Therapeutics by 47.7% during the 1st quarter. Vanguard Group Inc. now owns 3,440,270 shares of the company’s stock valued at $97,669,000 after acquiring an additional 1,110,629 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Up 0.5 %

Shares of DYN stock opened at $36.59 on Friday. The firm has a market cap of $3.20 billion, a P/E ratio of -9.22 and a beta of 1.07. The company has a 50 day moving average of $41.17 and a 200-day moving average of $33.49. Dyne Therapeutics has a 12-month low of $6.40 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.02. As a group, equities analysts expect that Dyne Therapeutics will post -2.96 EPS for the current year.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.